5-[2-(4-Fluorophenyl)-7-(4-hydroxypiperidin-1-yl)pyrazolo[1,5-c]pyrimidin-3-yl]-1,3-dihydroindol-2-one

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson announced positive early-stage trial results for its experimental prostate cancer drug JNJ-6143, acquired through a $3.05 billion Halda Therapeutics deal. The drug demonstrated signi